Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

11.12.23	Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks (PR Newswire)
08.12.23	Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend (PR Newswire)
05.12.23	Eli Lilly To Present Final Survival Results Of MONARCH 3 Trial Of Verzenio In Breast Cancer (RTTNews)
05.12.23	Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer S... (PR Newswire)
05.12.23	Eli Lilly Announces Availability Of Zepbound In U.S. Pharmacies - Quick Facts (RTTNews)
05.12.23	Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity (PR Newswire)
04.12.23	Lilly Says Tender Offer Expiration Extended Related To POINT Biopharma Acquisition (RTTNews)
04.12.23	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 (PR Newswire)
02.12.23	Lilly's Jaypirca Gets Second Approval From FDA (RTTNews)
01.12.23	Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Thera... (PR Newswire)
28.11.23	Lilly To Open New Gateway Labs Location In Partnership With Alexandria Real Estate Equities (RTTNews)
28.11.23	Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego (PR Newswire)
28.11.23	Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego (PR Newswire)
17.11.23	Eli Lilly To Construct A New $2.5 Billion High-tech Manufacturing Site In Alzey, Germany (RTTNews)
17.11.23	Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany (PR Newswire)
17.11.23	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 (PR Newswire)
15.11.23	Lilly Receives NRC Consent In Connection With Proposed Acquisition Of POINT Biopharma (RTTNews)
14.11.23	Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma (PR Newswire)
14.11.23	Lilly to Participate in Evercore ISI HealthCONx Conference (PR Newswire)
09.11.23	Lilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16 (RTTNews)
09.11.23	Lilly : FDA Approves Zepbound For Chronic Weight Management, New Option For Treatment Of Obesity (RTTNews)
08.11.23	Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma (PR Newswire)
08.11.23	FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems (PR Newswire)
02.11.23	Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting (PR Newswire)
02.11.23	Eli Lilly Cuts Annual Earnings Outlook Below View - Update (RTTNews)
02.11.23	Eli Lilly And Co. Q3 Earnings Summary (RTTNews)
02.11.23	Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity (PR Newswire)
01.11.23	Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease (PR Newswire)
01.11.23	Lilly Declares Fourth-Quarter 2023 Dividend (PR Newswire)
27.10.23	FDA Approves Lilly's Omvoh For Ulcerative Colitis Treatment (RTTNews)
27.10.23	FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis (PR Newswire)
26.10.23	Lilly to Participate in UBS Biopharma Conference 2023 (PR Newswire)
21.10.23	Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and... (PR Newswire)
20.10.23	Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement (PR Newswire)
20.10.23	Eli Lilly Reports Five-year Outcomes From Pre-planned Analysis Of Phase 3 MonarchE Study (RTTNews)
20.10.23	Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer (PR Newswire)
20.10.23	Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years (PR Newswire)
16.10.23	Lilly's Tirzepatide Shows Addl 21.1% Weight Loss After 12 Weeks Of Intensive Lifestyle Intervention (RTTNews)
16.10.23	Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks (PR Newswire)
12.10.23	Lilly: Mirikizumab Phase 3 Trial In Adults With Crohn's Disease Meets Coprimary Endpoints (RTTNews)
12.10.23	Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial (PR Newswire)
06.10.23	Lilly Announces Details of Presentations at ESMO Congress 2023 (PR Newswire)
04.10.23	Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
04.10.23	Lilly Announces Leadership Transitions (PR Newswire)
03.10.23	Lilly To Acquire POINT Biopharma For $1.4 Bln In Cash; POINT Up In Pre Market (RTTNews)
03.10.23	Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies (PR Newswire)
02.10.23	Eli Lilly: FDA Issues CRL For Lebrikizumab BLA Related To Third-party Manufacturing Organization (RTTNews)
02.10.23	U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer (PR Newswire)
22.09.23	Eli Lilly: FDA Approves Jardiance In Treatment Of Chronic Kidney Disease (RTTNews)
22.09.23	US FDA approves Jardiance® for the treatment of adults with chronic kidney disease (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

29.12.24		Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen
27.12.24		Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus
27.12.24		BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester
27.12.24		Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen
27.12.24		SLI-Handel aktuell: Zum Handelsende Gewinne im SLI
27.12.24		Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester
27.12.24		Börse Frankfurt: DAX zum Handelsende auf grünem Terrain
27.12.24		Börse Europa: Euro STOXX 50 verbucht zum Ende des Freitagshandels Zuschläge

29.12.24

Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen

27.12.24

Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus

27.12.24

BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester

27.12.24

Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen

27.12.24

SLI-Handel aktuell: Zum Handelsende Gewinne im SLI

27.12.24

Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester

27.12.24

Börse Frankfurt: DAX zum Handelsende auf grünem Terrain

27.12.24

Börse Europa: Euro STOXX 50 verbucht zum Ende des Freitagshandels Zuschläge

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Eli Lilly

Aktien Top/Flop

Eli Lilly Peer Group Nachrichten

Meistgelesene Nachrichten